PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. (PMCB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pmcb · pe ratio · data through Apr 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for PharmaCyte Biotech, Inc. (PMCB) measures how much investors pay for each dollar of the company's trailing earnings. PMCB's current PE ratio of N/A is calculated by dividing its stock price of $0.70 by its TTM earnings per share of -$0.35.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-04-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
PharmaCyte Biotech, Inc.You PMCB | $5M | N/A | — | -$0.35 |
 Brainstorm Cell Therapeutics Inc. BCLI | $9M | N/A | — | -$1.11 |
 Cyclerion Therapeutics, Inc. CYCN | $13M | N/A | — | -$1.09 |
 Impact BioMedical Inc. IBO | $7M | N/A | — | -$0.38 |
 Pasithea Therapeutics Corp. KTTA | $4M | N/A | — | -$2.91 |
 NovaBay Pharmaceuticals, Inc. NBY | $39M | N/A | — | -$3.80 |
 Polyrizon Ltd. PLRZ | $14M | N/A | — | -$2.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-04-30Latest FY2025 | 0.30x | $4.18 | -99.5% | |
2024-04-30 FY2024 | 60.86x | $0.03 | — | |
2023-04-30 FY2023 | — | $-0.22 | — | |
2022-04-30 FY2022 | — | $-0.27 | — | |
2021-04-30 FY2021 | — | $-2.45 | — | |
2020-04-30 FY2020 | — | $-4.23 | — | |
2019-04-30 FY2019 | — | $-5.55 | — | |
2018-04-30 FY2018 | — | $-10.58 | — | |
2017-04-30 FY2017 | — | $-7.89 | — | |
2016-04-30 FY2016 | — | $-12.09 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for PharmaCyte Biotech, Inc. (PMCB) measures how much investors pay for each dollar of the company's trailing earnings. PMCB's current PE ratio of N/A is calculated by dividing its stock price of $0.70 by its TTM earnings per share of -$0.35.
Frequently asked questions
PMCB pe ratio · 6 questionsPMCB's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.70 and TTM EPS of -$0.35. Data sourced from Financial Modeling Prep via PMCB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · PharmaCyte Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08